Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres

T. Smith · P. F. van Dessel · D. A. M. J. Theuns · A. Muskens-Heemskerk · R. T. van Domburg · A. A. Wilde · L. Jordaens

Published online: 20 July 2011 © The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract

Background The benefit of implantable defibrillators (ICDs) for primary prevention remains debated. We analysed the implications of prophylactic ICD implantation according to the guidelines in 2 tertiary hospitals, and made a healthcare utilisation inventory.

Methods The cohort consisted of all consecutive patients with coronary artery disease (CAD) or dilated cardiomyopathy (DCM) receiving a primary prophylactic ICD in a contemporary setting (2004–2008). Follow-up was obtained from hospital databases, and mortality checked at the civil registry. Additional data came from questionnaires sent to general practitioners.

Results There were no demographic differences between the 2 centres; one had proportionally more CAD patients and more resynchronisation therapy (CRT-D). The 587 patients were followed over a median of 28 months, and 50 (8.5%) patients died. Appropriate ICD intervention occurred in 123 patients (21%). There was a small difference in intervention-free survival between the 2 centres. The questionnaires revealed 338 hospital admissions in 52% of the responders. Device-related admissions happened on 68 occasions, in 49/276 responders. The most frequently reported ICD-related admission was due to shocks (20/49 patients); for other cardiac problems it was mainly heart failure (52/99). Additional outpatient visits occurred in 19%.

Conclusion Over a median follow-up of 2 years, one fifth of prophylactic ICD patients receive appropriate interventions. A substantial group undergoes readmission and additional visits. The high number of admissions points to a very ill population. Overall mortality was 8.5%. The 2 centres employed a similar procedure with respect to patient selection. One centre used more CRT-D, and observed more appropriate ICD interventions.

Keywords Complications · Coronary artery disease · Dilated cardiomyopathy · Health care resources · Implantable cardioverter defibrillator · Primary prevention · Mortality · Sudden cardiac death · Ventricular arrhythmias

Introduction

Implantable defibrillator (ICD) therapy is without doubt the most effective therapy available to prevent sudden cardiac death (SCD) in selected patient groups [1–5]. Convincing evidence of the effectiveness of primary prophylactic ICD therapy exists for coronary artery disease (CAD) and dilated cardiomyopathy (DCM) [6–10]. Like most state-of-the-art therapeutic modalities, ICD therapy is costly [11–17]. With the current improvement in heart failure therapy, the recent increased number of device recalls, and the trend towards more lead failure, the debate about prophylactic ICD therapy has shifted from ‘effectiveness’ towards ‘cost-effectiveness’ [18–22]. Nevertheless, some authors remain convinced that a serious underutilisation continues to exist in Europe [23, 24].
mostly those that prevent costly events—are cost-effective. In
contrast, ICD therapy prevents SCD, an event that costs little
to nothing to treat, when an ICD is in place [25]. Cost-
effectiveness analyses showed that a large part of the lifetime
costs of a primary prophylactic ICD patient occur at the time
of ICD implantation. However, it takes years to accrue the
benefit of a primary prophylactic ICD since this effect is
time-dependent. In this perspective, the health care costs that
accumulate during these years (i.e. hospitalisation costs, costs
for unscheduled outpatient consultations) should also
be taken into account when analysing the cost-effectiveness,
especially when considering that primary prevention ICD
candidates are heart failure patients with a potential high
need for specialised care. Unfortunately, no data on the
burden of medical care are available in a real world setting
for this kind of patients in the Netherlands.

The aim of this study was to analyse the frequency of
hospitalisation and unscheduled outpatient consultations in
primary prophylactic ICD patients, as documented in the
hospital records of 2 major university hospitals, supplemented
with data obtained with a survey among general practitioners,
who could provide data on otherwise unknown admissions in
other institutions.

Methods

Study population

The study population consisted of all consecutive patients with
CAD or DCM, who received an ICD according to the ESC/
AHA/ACC 2006 guidelines for primary prophylaxis of sudden
cardiac death in the Erasmus MC between January 2004 and
July 2008, and of all similar consecutive patients in the
Amsterdam University Medical Centre (AMC) in the year
2006. The presence of CAD had to be documented clinically
by a history of a myocardial infarction according to the
definitions by ACC/AHA/ESC, if coronary artery bypass
grafting (CABG) or a percutaneous coronary intervention
(PCI) had been performed, or if significant coronary artery
stenosis was documented with coronary angiography. DCM
was defined as a primary myocardial disease with dilatation
without valvular or congenital aetiology. Patients with channe-
lopathies and specific diseases as arrhythmogenic right ventric-
ular cardiomyopathy and the Brugada syndrome were
excluded. All ICDs were implanted by a transvenous technique
in the cardiac catheterisation laboratory, or if necessary by a
cardiac surgeon (e.g. for placement of epicardial leads).

Data collection

Baseline characteristics included age, gender, underlying
disease, presence of prior myocardial infarction, and left
ventricular function at the time of ICD implantation.
Follow-up started at the time of ICD implantation, with
conventional ICD control. All patients were followed at 3-
month intervals and were advised to contact the outpatient
clinic after a symptomatic event. At each follow-up visit,
arrhythmic events with stored electrograms (EGMs) were
retrieved from the device’s memory. Two independent
reviewers analysed the stored electrograms to classify the
arrhythmia and assess the appropriateness of device
classification and therapy. In case of disagreement, a third
reviewer was consulted to provide the final diagnosis.

The electronic hospital files and the electronic ICD
database were reviewed to record and understand the impact
of complications. Procedure-related complications were de-
defined as occurring within 30 days after implantation.

In order to make a better health care utilisation inventory,
we sent questionnaires to the general practitioners of 464 of
the included patients (all AMC and the first 355 Erasmus
MC patients). This questionnaire examined the frequency
and duration of hospital admissions for ICD-related prob-
lems, hospital admissions for non-ICD related cardiac
problems, and hospital admissions for other conditions.
We also asked for the number of additional outpatient visits.
Regular outpatient control visits and admissions for elective
ICD generator replacements because of battery depletion
were not taken into account. Follow-up for vital status was
obtained by consulting the civil registry. The duration of the
hospitalisation was only obtained from the AMC sample.
Follow-up was completed until 31 December 2008.

Statistical analysis

Continuous variables are expressed as the mean ± SD, or as
the median with the interquartile range (IQR) when not
normally distributed. Categorical variables are expressed as
frequency (percentage). Group differences were analysed
with Chi-square tests and independent sample T-tests where
appropriate. The assumption of normality was checked for
all variables tested. If not normally distributed, we used
non-parametric tests. Alpha was set at 0.05 for all statistical
tests. Cumulative survival and event-free rates of appropri-
ate ICD therapy were calculated according to the Kaplan-
Meier method and were compared with the log-rank test.
Patients who underwent heart transplantation were censored
alive from the moment of transplantation.

Results

Study population

The study population consisted of a total group of 587
patients: 478 patients originated from the Erasmus MC
Rotterdam, 109 patients from the AMC Amsterdam. The baseline characteristics of the study population are presented in Table 1. The median follow-up till death or the closure date was 28 months (IQR 14–37 months). The follow-up of the Erasmus MC patients was shorter (Table 2). There were slightly more patients with CAD in the group from the Erasmus MC. The mean ejection fraction was the same. There were 5% of the patients in NYHA class I, 51% in NYHA class II, 44% in class III, and only 1% in class IV. Heart transplantation was performed in 17 patients of a total of 41 patients who were on the transplantation list of the Erasmus MC. There were significant differences in the device type used in the two centres, with the Erasmus MC using more cardiac resynchronisation therapy systems with defibrillation (CRT-D).

Mortality

During the reported follow-up, 50 patients (8.5%) died (Table 2), at a median time since implantation of 359 days (IQR 159–759 days). The survival curves for Erasmus MC patients and AMC patients are depicted in Fig. 1. No significant differences in mortality was observed between Erasmus MC patients and AMC patients (log rank = 0.573; NS).

ICD interventions

During follow-up, 123 patients (21%) experienced at least one episode of ventricular tachyarrhythmia triggering appropriate ICD intervention, including 16/50 of the deceased patients (32%), and 9/41 patients (22%) who were on the heart transplantation list. The median interval to the first appropriate ICD intervention was 251 days (IQR 65–507 days). Differences in this parameter between the 2 institutions were not significant. Figure 2 shows the Kaplan-Meier curves for appropriate ICD interventions for patients originating from both centres. Nevertheless, the cumulative incidence of appropriate ICD interventions was significantly higher in Erasmus MC patients compared with AMC Amsterdam patients (log rank = 4.340; p-value=0.037).

Readmissions for lead and ICD problems

As obtained from the patient records, there were 54 late complications in 47 patients (8%), similar for both hospitals. This included 8 lead repositions, 12 lead replacements of which 3 were because of a recall (Sprint Fidelis). A total number of 27 ICD replacements occurred, including 15 replacements within 36 months and 3 pocket infections. There were no recalls for pulse generators in this time frame in both institutions.

Hospitalisation and unscheduled outpatient consultations

A questionnaire was sent to 464 patients. A completed questionnaire was received from 276 patients, making the response rate 59%. A total number of 338 hospital admissions were reported, occurring in 144 patients (52% of the responders, and 31% of the group to whom a questionnaire was sent). In total, 79/144 were admitted twice; of these, 44 a third time, and 27 at least 4 times. The median interval between ICD implantation and first hospitalisation was 407 days (IQR 132–800 days). The cumulative incidence of first hospitalisation after ICD implantation is depicted in Fig. 3. No significant difference is observed between the centres.

Analysis of the questionnaires is presented in Table 3. The median duration of hospitalisation was 2.5 days (IQR 1–12 days).

From the 338 reported hospital admissions, 68 (20%) were ICD related; 180 (53%) were for other cardiac reasons, and 90 (27%) were for non-cardiac pathology. Figure 4 shows the distribution of the reasons per

| Table 1 Baseline characteristics |
|-----------------------------------|
| Characteristic                    | Erasmus MC n=478 | AMC n=109 | p value |
| Mean follow-up (days)            | 762±446          | 969±185   | <0.0001 |
| Age (years)                      | 59±12            | 61±12     | NS      |
| Male gender                      | 374 (78%)        | 84 (77%)  | NS      |
| Coronary artery disease          | 319 (67%)        | 61 (56%)  | 0.023   |
| Dilated cardiomyopathy           | 159 (33%)        | 45 (41%)  | NS      |
| LVEF (%)                         | 25±8             | 22±6      | NS      |
| ICD type                         |                   |           |         |
| Single chamber                   | 200 (42%)        | 65 (61%)  | <0.001  |
| Dual chamber                     | 74 (15%)         | 38 (35%)  |         |
| CRT-D                            | 204 (43%)        | 4 (4%)    |         |

CRT-D cardiac resynchronisation therapy defibrillator; LVEF left ventricular ejection fraction; NA not available
admission category. Of 49 patients with an ICD-related admission, 20 were admitted because of a shock (41%); of 99 patients with other cardiac admissions, heart failure or associated conditions were the reason in 52 occasions (53%). The largest non-cardiological reason for hospital admission was related to internal medicine (25/58 patients).

Additional unscheduled cardiac outpatient consultations were observed in 51 (19%) of the patients (Table 3).

**Discussion**

This study of patients in two different Dutch university hospitals shows that in spite of an apparent different attitude, but with formal adherence to the actual guidelines, the outcome of the patients was completely comparable with respect to a hard endpoint as mortality, and to a softer endpoint as hospitalisation [26]. Nevertheless, we have seen differences in the underlying cardiac disease of the patients (the prevalence of coronary artery disease was higher in Rotterdam), and in the type of implanted defibrillation systems (higher number of CRT-D; also in Rotterdam). The only different outcome between the 2 centers was the occurrence of appropriate ICD therapy, which can not be explained at first glance.

**Mortality** The mortality is less than 10% in both centres, even with a median follow-up of more than 2 years. These data correspond with recent real world data [27, 28]. The landmark trials (MADIT, MADIT II, SCDHeFT) all had a mortality rate in the active arm of 14, 22 and 18%, respectively, at 3 years [1–3]. This implicates that today, the practice in the Netherlands can still be compared with the trials as they were published. The outcome of the heart transplantation patients, a typically censored group, was not different in this respect from the others.

**Appropriate ICD interventions (shocks/antitachycardia pacing)** In both centres, approximately one fifth of the patients received appropriate ICD interventions, over a median follow-up of more than 2 years. This intervention rate is high, and supports the idea that the right patients were selected. This patient selection was in line with the actual guidelines and was more or less conservative,
meaning that early post infarct patients were avoided, in line with recent studies [29, 30]. It is striking that one centre had a higher rate of device therapy than the other, which might be attributed to the presence of patients with advanced heart failure (as might be suggested by the higher proportion of CRT-D) or simply to different programming strategies. The latter is a very likely explanation. Although, there was no obvious difference in the standard programming of rate cut-offs for arrhythmia detection. On the other hand, differences in time to intervention, and the use of ATP may certainly influence the rate of interventions [31]. It is reassuring to observe that this higher intervention rate is not associated with a different mortality or real morbidity. Further, in both centres, the rate of inappropriate interventions was low as is reported elsewhere [32].

**Morbidity** The readmission rate was very high, and the questionnaire did not really yield a different outcome in respect to what was known from the hospital files e.g. for lead reintervention. This supports the idea that the questionnaire was reliable as well as the observation that these patients were very ill, with a high readmission rate, also for non-cardiac causes. This might be an indication that more attention should be given to comorbidity in general, before implantation [33–35]. It is known that diabetes, renal failure and high age contribute to the morbidity after implantation. Further, not all cardiac admissions occurred because of device therapy. Only a minority of admissions were reported to occur because of shock therapy. The most important reason for admission remains heart failure, which confirms previous findings [38, 39].

**Limitations**

It might be that our method (the survey) resulted in over-reporting, as general practitioners might have responded more frequently if they had encountered problematic patients. However, it was the only way to understand what was happening with the patients at home and in the referral centre. Further, the rate of specific complications as reported coincided with the rate as known from the hospital records.

**Conclusions**

The 2 centres behaved in a similar way with respect to patient selection. Mortality and readmission were the same during follow-up. However, one centre more often used CRT, and observed a higher ICD therapy rate for ventricular arrhythmias.

Further, the high readmission rate, mainly for heart failure, is a reason to organise a good follow-up for these patients. It is clear that the referring cardiologist still has a role after implantation. This role could even increase when it is accepted that ICD control is performed in those centres. On the other hand, the high early complication rate demands a tight control to improve the quality at the time of implantation. One important measure could be to maintain a limited number of experienced implanting centres [36, 37]. It is clear that patient selection, according to the actual guidelines, results in a reproducible outcome, even in different centres.
Conflicts of interest  T. Smith: nothing to declare. P. van Dessel: nothing to declare. D.A.M.J. Theuns received research grants from Biotronik, Boston Scientific, St Jude Medical, and he is a consultant to Cameron Health. A. Muskens and R.T. van Domburg: nothing to declare. A.A.W. Wilde: nothing to declare. L. Jordaens received research grants and speaker fees from Biotronik, Boston Scientific, Cameron Health, Medtronic, Sorin, and St Jude Medical.

Open Access  This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.

2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.

3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.

4. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2006;8:746-837.

5. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: Executive Summary. Heart Rhythm. 2008;5:934-55.

6. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-12.

7. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453-8.

8. Kadish A, Dyer A, Daubert JP, et al. Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8.

9. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874-9.

10. Theuns DAMJ, Smith T, Hunink MGM, et al. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronisation in patients with ischaemic or nonischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12:1564-70.
11. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471–80.

12. Zwanziger J, Hall J, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators. Results from the multicenter automatic defibrillator implantation trial (MADIT)-II. JACC. 2006;47:2310–8.

13. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or Amiodarone in chronic stable heart failure. Circulation. 2006;114:135–42.

14. Caro JJ, Ward A, Deniz HB, et al. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus Amiodarone. Value Health. 2007;10:13–22.

15. Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11:716–26.

16. Neyt M, Thiry N, Ramaekers D, et al. Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy. 2008;6:67–80.

17. Van Brabandt H, Neyt M. Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium. Europace. 2009;11:1571–3.

18. Hauser RG. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol. 2005;45:2022–5.

19. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA. 2006;295:1901–6.

20. Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115:2474–80.

21. Maisel WH, Kramer DB. Implantable cardioverter-defibrillator lead performance. Circulation. 2008;117:2721–3.

22. Hauser RG, Hayes DL. Increasing hazard of Sprint Fidelis implantable cardioverter-defibrillator lead failure. Heart Rhythm. 2009;6:605–10.

23. Borleffs C, Wilde A, Cramer J, et al. Clinical implementation of guidelines for cardioverter defibrillation implantation: lost in translation? Neth Heart J. 2007;15:129–32.

24. Camm AJ, Nisam S. European utilization of the implantable defibrillator: has 10 years changed the ‘enigma’? Europace. 2010;12:1063–9.

25. Camm J, Klein H, Nisam S. The cost of implantable defibrillators: perceptions and reality. Eur Heart J. 2007;28:392–7.

26. Wilde A, Simmers T. Primary prevention, are we on the right track? Neth Heart J. 2009;17:92–4.

27. Santini M, Russo M, Botto G, et al. Clinical and arrhythmic outcomes after implantation of a defibrillator for primary prevention of sudden death in patients with post-myocardial infarction cardiomyopathy: The Survey to Evaluate Arrhythmia Rate in High-risk MI patients (SEARCH-MI). Europace. 2009;11:476–82.

28. Gradaus R, Block M, Brachmann J, et al. Mortality, morbidity, and complications in 3344 patients with implantable cardioverter defibrillators: results from the German ICD Registry EURID. Pacing Clin Electrophysiol. 2003;26:1511–8.

29. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–8.

30. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427–36.

31. Wathen MS, DeGroot PJ, Sweeney MO, et al. PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110:2591–6.

32. Theuns DA, Rivero-Ayerza M, Goedhart DM, et al. Morphology discrimination in implantable cardioverter-defibrillators: consistency of template match percentage during atrial tachyarrhythmias at different heart rates. Europace. 2008;10:1060–6.

33. Pellegrini CN, Lee K, Olgin JE, et al. Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace. 2008;10:1296–301.

34. Cygankiewicz I, Gillespie J, Zareba W, et al. Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators. Heart Rhythm. 2009;6:468–73.

35. Theuns DAMJ, Schaar B, Soliman OII, et al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace. 2011;13:62–9.

36. Al-Khatib SM, Lucas FL, Jollis JG, et al. The relation between patients’ outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol. 2005;46:1536–40.

37. Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009;301:1661–70.

38. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrrhythmia by an implanted defibrillator. Circulation. 2004;110:3760–5.

39. Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation. 2006;113:2810–7.